BIIB Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$234.35median target· current $202.95 (+15.5%)36 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
27 articles · sorted by datePage 1 of 2 · 27 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio36.11Forward 17.30
EPS (TTM)$5.62-84.8% YoY
Profit margin8.3%HEALTHCARE
Market cap$29.99BLarge cap
Valuation
- Forward P/E
- 17.30
- PEG ratio
- 5.09
- P/B
- 1.59
- P/S (TTM)
- 2.99
- EV/EBITDA
- 17.32
Profitability & growth
- ROE (TTM)
- 4.6%
- Operating margin
- 25.1%
- Revenue growth YoY
- 3.4%
- Dividend yield
- —
- Beta
- 0.16
Last earnings
Jul 29, 2026 · Estimate $3.04 · Reported $3.60
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Biogen Inc
Company profileBiogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 225 BINNEY STREET, CAMBRIDGE, MA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$29.99B
Shares outstanding$147.8M
52W high$219.72
52W low$127.00
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent